Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Aug 17, 2021
Date Accepted: Nov 27, 2021

The final, peer-reviewed published version of this preprint can be found here:

Hearing Loss in Patients With Morquio Syndrome: Protocol for a Scoping Review

Diaz-Ordoñez L, Candelo E, Silva-Cuero K, Saldarriaga W, Murgasova L, Magner M, Pachajoa H

Hearing Loss in Patients With Morquio Syndrome: Protocol for a Scoping Review

JMIR Res Protoc 2022;11(6):e32986

DOI: 10.2196/32986

PMID: 35671071

PMCID: 9214610

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Hearing loss in Morquio disease: a scoping review protocol

  • Lorena Diaz-Ordoñez; 
  • Estephania Candelo; 
  • Katherine Silva-Cuero; 
  • Wilmar Saldarriaga; 
  • Lenka Murgasova; 
  • Martin Magner; 
  • Harry Pachajoa

ABSTRACT

Objective:

This scoping review aimed to understand the extent and type of evidence in relation to physiopathology, classification, epidemiology, clinical management, and effect of therapy for hearing loss in patients with mucopolysaccharidosis (MPS) IVA. Introduction: Mild to moderate hearing loss is common in patients with MPS IVA. The hearing loss can be conductive, sensorineural, or mixed. However, in these patients, the mixed form is frequent, attributed to the combination of conductive and neurosensory elements, with a slowly progressive evolution. Conductive hearing loss may be secondary to recurrent upper respiratory tract infections, serous otitis media, and deformity of the ear ossicles due to accumulation of glycosaminoglycans (GAGs). Meanwhile, the sensorineural form is mainly attributed to the accumulation of GAG in the auditory system.. Inclusion criteria: This scoping review include participants of both sexes, without specific age, who are diagnosed with mucopolysaccharidosis IVA and who develop hearing loss as a comorbidity. None exclusion criteria (country, language or document type) will be applicable.

Methods:

This scoping review includes participants of both sexes, without specific age, who are diagnosed with MPS IVA and develop hearing loss as comorbidity. No exclusion criteria (country, language, or document type) will be applicable. The information sources will include experimental and quasi-experimental, analytical observational, observational, and qualitative studies. Unpublished literature will not be covered. Gray literature will not be covered. Two independent reviewers will participate in the process of screening the literature, paper selection, and data extraction, and this process will be performed blindly. When all manuscripts have been selected by two reviewers, disagreements that arise between the reviewers at each stage of the selection process will be resolved through discussion or with an additional reviewer. Results will be reported with descriptive statistics and diagrammatic or tabular displayed information as explained in the JBI guidelines.


 Citation

Please cite as:

Diaz-Ordoñez L, Candelo E, Silva-Cuero K, Saldarriaga W, Murgasova L, Magner M, Pachajoa H

Hearing Loss in Patients With Morquio Syndrome: Protocol for a Scoping Review

JMIR Res Protoc 2022;11(6):e32986

DOI: 10.2196/32986

PMID: 35671071

PMCID: 9214610

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.